Scaffold Searching of FDA and EMA-Approved Drugs Identifies Lead Candidates for Drug Repurposing in Alzheimer’s Disease
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
In: Frontiers in Chemistry (2021) 9:736509. doi: 10.3389/fchem.2021.736509
- Ereignis
-
Veröffentlichung
- (wo)
-
Würzburg
- (wer)
-
Universität Würzburg
- (wann)
-
2022
- Urheber
- DOI
-
10.3389/fchem.2021.736509
- URN
-
urn:nbn:de:bvb:20-opus-248703
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:33 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Shityakov, Sergey
- Skorb, Ekaterina V.
- Förster, Carola Y.
- Dandekar, Thomas
- Universität Würzburg
Entstanden
- 2022
Ähnliche Objekte (12)
Repurposing FDA-approved drugs for anti-aging therapies
Repurposing FDA‐Approved Compounds for the Discovery of Glutaminyl Cyclase Inhibitors as Drugs Against Alzheimer's Disease
Repurposing von FDA-approved drugs zur Therapie des humanen Cytomegalievirus
Repurposing FDA approved drugs against the human fungal pathogen, Candida albicans
Repurposing FDA approved drugs as radiosensitizers for treating hypoxic prostate cancer
Computational prognostic evaluation of Alzheimer’s drugs from FDA-approved database through structural conformational dynamics and drug repositioning approaches
Repurposing of approved cardiovascular drugs
Single-cell-led drug repurposing for Alzheimer’s disease
In silico repurposing of antipsychotic drugs for Alzheimer’s disease
Repurposing FDA-approved drugs as inhibitors of therapy-induced invadopodia activity in glioblastoma cells
The First FDA-Approved Antibody-Drug Conjugate
A systematic analysis of FDA-approved anticancer drugs
Repurposing FDA-approved drugs for anti-aging therapies
Repurposing FDA‐Approved Compounds for the Discovery of Glutaminyl Cyclase Inhibitors as Drugs Against Alzheimer's Disease
Repurposing von FDA-approved drugs zur Therapie des humanen Cytomegalievirus
Repurposing FDA approved drugs against the human fungal pathogen, Candida albicans
Repurposing FDA approved drugs as radiosensitizers for treating hypoxic prostate cancer
Computational prognostic evaluation of Alzheimer’s drugs from FDA-approved database through structural conformational dynamics and drug repositioning approaches
Repurposing of approved cardiovascular drugs
Single-cell-led drug repurposing for Alzheimer’s disease
In silico repurposing of antipsychotic drugs for Alzheimer’s disease
Repurposing FDA-approved drugs as inhibitors of therapy-induced invadopodia activity in glioblastoma cells
The First FDA-Approved Antibody-Drug Conjugate
A systematic analysis of FDA-approved anticancer drugs
Repurposing FDA-approved drugs for anti-aging therapies
Repurposing FDA‐Approved Compounds for the Discovery of Glutaminyl Cyclase Inhibitors as Drugs Against Alzheimer's Disease
Repurposing von FDA-approved drugs zur Therapie des humanen Cytomegalievirus
Repurposing FDA approved drugs against the human fungal pathogen, Candida albicans
Repurposing FDA approved drugs as radiosensitizers for treating hypoxic prostate cancer
Computational prognostic evaluation of Alzheimer’s drugs from FDA-approved database through structural conformational dynamics and drug repositioning approaches
Repurposing of approved cardiovascular drugs
Single-cell-led drug repurposing for Alzheimer’s disease
In silico repurposing of antipsychotic drugs for Alzheimer’s disease
Repurposing FDA-approved drugs as inhibitors of therapy-induced invadopodia activity in glioblastoma cells
The First FDA-Approved Antibody-Drug Conjugate